Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaleido Biosciences Inc.

kaleido.com

Latest From Kaleido Biosciences Inc.

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

Financing StartUps and SMEs

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kaleido Biosciences Inc.
  • Senior Management
  • Alison Lawton, Pres. & CEO
    Joshua Brumm, COO & CFO
    Johan van Hylckama Vlieg, PhD, CSO
    John W Davies, PhD, CTO
    Katharine Knobil, MD, Head, R&D & CMO
    Clare Fisher, CBO
  • Contact Info
  • Kaleido Biosciences Inc.
    Phone: (617) 674-9000
    65 Hayden Ave.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register